Biotech Review of the Year
The main challenge in 2023 was that global economic conditions (war in Ukraine, war in the Middle East, increasing interest rates) continued to negatively impact the capital markets and the fundraising environment. This has been demonstrated with the slowdown in the number of biotech companies attempting to IPO, but has also started to be felt in the private markets. There is continued downward pressure on valuations and all companies are trying to extend their runway to get to a larger value inflection point.
Page 54
MORERelated News
Introducing Fierce Biotech’s 2024 Fierce 15 – OMass Therapeutics
August 5, 2024
What makes OMass fierce: You can’t fault OMass for its ambition. The company may still be in preclinical development, but it...
Dame Carol Robinson to receive Lifetime Achievement Award for groundbreaking protein analysis work
June 25, 2024
The European Patent Office (EPO) has announced that Dame Carol Robinson, Professor of Chemistry at the University of Oxford, will receive...
5 Pharmaceutical Companies in the UK to Know
March 11, 2024
OMass uses high-resolution mass spectrometry to study protein assemblies and discover new medicines. Its spectrometry platform, called OdyssION, enables better visualization...
